10-K/A: SeaStar Medical Files Amendment No. 1 to Form 10-K, Addressing Omitted Information and Correcting Errors

SeaStar Medical Holding Corporation files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information, correct typographical errors, and file new certifications.

Summary

• SeaStar Medical Holding Corporation is filing Amendment No. 1 on Form 10-K/A for the year ended December 31, 2024.
• The amendment addresses the omission of information required by Part III of Form 10-K from the original filing.
• The amendment includes the correction of dates on Exhibits 32.1 and 32.2.
• The amendment includes the filing of new certifications from the principal executive officer and principal financial officer.
• The original Form 10-K was filed with the SEC on March 27, 2025.
• The amendment updates the date as of which the number of outstanding shares of the Company's common stock is being provided.
• The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Capital Market on June 28, 2024, was $23.9 million.
• The number of shares of Registrant's Common Stock outstanding as of April 16, 2024, was 9,803,074.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. The corrections and additions suggest a commitment to accuracy and compliance, which is viewed positively.

Positives

• The company is taking steps to ensure full compliance with SEC reporting requirements.
• The amendment addresses and corrects identified deficiencies in the original filing.

Negatives

• The need to file an amendment indicates initial errors or omissions in the original Form 10-K.

Risks

• Failure to maintain compliance with SEC reporting requirements could result in penalties or other adverse consequences.

Future Outlook

The document does not contain specific forward-looking statements beyond the standard disclosures and corrections.

Industry Context

This filing is a routine amendment to a standard SEC form, ensuring compliance and transparency for investors in the medical device industry.

Comparison to Industry Standards

• The information provided in the amendment is consistent with standard SEC reporting requirements for publicly traded companies.
• The executive compensation disclosures align with those of smaller reporting companies in the medical device sector.
• The corporate governance practices described are typical for companies listed on the Nasdaq.

Stakeholder Impact

• The amendment ensures that stakeholders have access to accurate and complete information about the company.
• The corrections and additions may influence investor confidence and decision-making.

Next Steps

• The company will continue to operate under the corrected and updated information provided in the Form 10-K/A.

Key Dates

Keywords

Form 10-K/A, amendment, financial reporting, SEC, corporate governance, SeaStar Medical, executive compensation, directors, financial statements